United Therapeutics Corp (NASDAQ: UTHR) kicked off On Friday, up 7.13% from the previous trading day, before settling in for the closing price of $274.7. Over the past 52 weeks, UTHR has traded in a range of $266.98-$417.82.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
While this was happening, its average annual earnings per share was recorded 10.68%. With a float of $44.08 million, this company’s outstanding shares have now reached $45.22 million.
The extent of productivity of a business whose workforce counts for 1305 workers is very important to gauge. In terms of profitability, gross margin is 88.98%, operating margin of 47.05%, and the pretax margin is 52.54%.
United Therapeutics Corp (UTHR) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Drug Manufacturers – Specialty & Generic Industry. The insider ownership of United Therapeutics Corp is 2.53%, while institutional ownership is 99.07%. The most recent insider transaction that took place on Jul 24 ’25, was worth 3,345,225. In this transaction EVP & GENERAL COUNSEL of this company sold 11,000 shares at a rate of $304.11, taking the stock ownership to the 36,781 shares. Before that another transaction happened on Jul 24 ’25, when Company’s Officer proposed sale 11,000 for $304.11, making the entire transaction worth $3,345,224.
United Therapeutics Corp (UTHR) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 10.68% per share during the next fiscal year.
United Therapeutics Corp (NASDAQ: UTHR) Trading Performance Indicators
Take a look at United Therapeutics Corp’s (UTHR) current performance indicators. Last quarter, stock had a quick ratio of 6.94. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.32. Likewise, its price to free cash flow for the trailing twelve months is 12.46.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 25.61, a number that is poised to hit 7.41 in the next quarter and is forecasted to reach 28.87 in one year’s time.
Technical Analysis of United Therapeutics Corp (UTHR)
The latest stats from [United Therapeutics Corp, UTHR] show that its last 5-days average volume of 1.02 million was superior to 0.51 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 25.13%.
During the past 100 days, United Therapeutics Corp’s (UTHR) raw stochastic average was set at 40.14%, which indicates a significant decrease from 62.27% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 8.48 in the past 14 days, which was lower than the 9.32 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $298.82, while its 200-day Moving Average is $331.09. Now, the first resistance to watch is $299.58. This is followed by the second major resistance level at $304.89. The third major resistance level sits at $313.17. If the price goes on to break the first support level at $285.99, it is likely to go to the next support level at $277.71. Assuming the price breaks the second support level, the third support level stands at $272.40.
United Therapeutics Corp (NASDAQ: UTHR) Key Stats
The company with the Market Capitalisation of 13.31 billion has total of 45,107K Shares Outstanding. Its annual sales at the moment are 2,877 M in contrast with the sum of 1,195 M annual income. Company’s last quarter sales were recorded 794,400 K and last quarter income was 322,200 K.
